HRA Pharma licenses ellaOne rights to Nycomed in certain territories

HRA Pharma, a privately-held,  French pharmaceutical company, has licensed rights to its emergency contraceptive ellaOne (ulipristal  acetate) in the Nordic and Baltic territories to Swiss drugmaker  Nycomed. The countries included in the accord are Denmark, Estonia,  Finland, Iceland, Latvia, Lithuania, Norway and Sweden. Nycomed says it  has a strong presence in women's health channels in these regions, and  has marketed HRA's emergency contraceptive NorLevo in the Nordic  countries for over a decade. ellaOne will complement this existing  portfolio of products. Last month, the Committee for Medicinal Products  for Human Use (CHMP) of the European Medicines Agency (EMEA)  recommended the next-generation emergency contraceptive for  approval (Marketletter March 30).